- Home
- BBOT vs FTRE Comparison
BBOT vs FTRE Comparison
Compare BBOT & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBOT | FTRE |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 864.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BBOT | FTRE |
|---|---|---|
| Price | $13.69 | $14.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | ★ $23.80 | $11.64 |
| AVG Volume (30 Days) | 168.9K | ★ 1.3M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.17 |
| Revenue Next Year | N/A | $0.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $8.50 | $3.97 |
| 52 Week High | $14.78 | $23.97 |
Technical Indicators
Market Signals| Indicator | BBOT | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 69.31 |
| Support Level | N/A | $12.12 |
| Resistance Level | N/A | $15.05 |
| Average True Range (ATR) | 0.00 | 0.99 |
| MACD | 0.00 | 0.33 |
| Stochastic Oscillator | 0.00 | 86.06 |
Price Performance
Historical ComparisonAbout BBOT BridgeBio Oncology Therapeutics Inc. Common Stock
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.